Trials / Completed
CompletedNCT03729349
Golimumab for Adherence in Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 222 (actual)
- Sponsor
- Janssen Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if non-adherence to Rheumatoid Arthritis (RA) drugs in participants treated with biologic disease modifying anti-rheumatic drugs (DMARDs) is associated with a greater incidence of disease in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Golimumab | Participants will receive golimumab as a part of clinical practice. |
Timeline
- Start date
- 2019-01-15
- Primary completion
- 2023-06-19
- Completion
- 2023-06-19
- First posted
- 2018-11-02
- Last updated
- 2024-07-18
Locations
32 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT03729349. Inclusion in this directory is not an endorsement.